Trial · NCT03316131
Results by group34
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 34
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Peak Urinary Excretion of Uric Acid (UA) on Day 7 | Treatment Sequence A+B | -12.87 | 95% Confidence Interval -21.03 to -4.70 | milligrams (mg) | |
| Change From Baseline in Peak Urinary Excretion of Uric Acid (UA) on Day 7 | Treatment Sequence B+A | -13.15 | 95% Confidence Interval -21.31 to -4.98 | milligrams (mg) | |
| Change From Baseline in Plasma Concentration (Cmax) on Day 7 | Treatment Sequence A+B | Verinurad | 17.52 | Geometric Coefficient of Variation 45.87 | ng/mL |
| Change From Baseline in Plasma Concentration (Cmax) on Day 7 | Treatment Sequence B+A | Verinurad | 15.26 | Geometric Coefficient of Variation 52.48 | ng/mL |
| Change From Baseline in Plasma Concentration (Cmax) on Day 7 | Treatment Sequence A+B | M1 | 25.28 | Geometric Coefficient of Variation 41.55 | ng/mL |
| Change From Baseline in Plasma Concentration (Cmax) on Day 7 | Treatment Sequence B+A | M1 | 25.61 | Geometric Coefficient of Variation 57.24 | ng/mL |
| Change From Baseline in Plasma Concentration (Cmax) on Day 7 | Treatment Sequence A+B | M8 | 18.45 | Geometric Coefficient of Variation 35.45 | ng/mL |
| Change From Baseline in Plasma Concentration (Cmax) on Day 7 | Treatment Sequence B+A | M8 | 18.42 | Geometric Coefficient of Variation 44.36 | ng/mL |
| Change From Baseline in Area Under Plasma Concentration Time Curve From Time Zero to the Time of Last Measurable Concentration (AUClast) on Day 7 | Treatment Sequence A+B | Verinurad | 149.1 | Geometric Coefficient of Variation 37.79 | h∙ng/mL |
| Change From Baseline in Area Under Plasma Concentration Time Curve From Time Zero to the Time of Last Measurable Concentration (AUClast) on Day 7 | Treatment Sequence B+A | Verinurad | 141.0 | Geometric Coefficient of Variation 44.90 | h∙ng/mL |
| Change From Baseline in Area Under Plasma Concentration Time Curve From Time Zero to the Time of Last Measurable Concentration (AUClast) on Day 7 | Treatment Sequence A+B | M1 | 212.7 | Geometric Coefficient of Variation 42.74 | h∙ng/mL |
| Change From Baseline in Area Under Plasma Concentration Time Curve From Time Zero to the Time of Last Measurable Concentration (AUClast) on Day 7 | Treatment Sequence B+A | M1 | 221.3 | Geometric Coefficient of Variation 49.13 | h∙ng/mL |
| Change From Baseline in Area Under Plasma Concentration Time Curve From Time Zero to the Time of Last Measurable Concentration (AUClast) on Day 7 | Treatment Sequence A+B | M8 | 174.2 | Geometric Coefficient of Variation 34.57 | h∙ng/mL |
| Change From Baseline in Area Under Plasma Concentration Time Curve From Time Zero to the Time of Last Measurable Concentration (AUClast) on Day 7 | Treatment Sequence B+A | M8 | 176.5 | Geometric Coefficient of Variation 36.85 | h∙ng/mL |
| Change From Baseline in Urinary Excretion of Serum UA (sUA) on Day 7 | Treatment Sequence A+B | -327.161 | 95% Confidence Interval -352.559 to -301.762 | umol/L | |
| Change From Baseline in Urinary Excretion of Serum UA (sUA) on Day 7 | Treatment Sequence B+A | -264.851 | 95% Confidence Interval -290.060 to -239.643 | umol/L | |
| Change From Baseline in Time to Reach Maximum Observed Concentration (Tmax) on Day 7 | Treatment Sequence A+B | Verinurad | 4.00 | Full Range 2.00 to 8.00 | hour |
| Change From Baseline in Time to Reach Maximum Observed Concentration (Tmax) on Day 7 | Treatment Sequence B+A | Verinurad | 4.00 | Full Range 3.00 to 8.08 | hour |
| Change From Baseline in Time to Reach Maximum Observed Concentration (Tmax) on Day 7 | Treatment Sequence A+B | M1 | 4.00 | Full Range 2.00 to 8.00 | hour |
| Change From Baseline in Time to Reach Maximum Observed Concentration (Tmax) on Day 7 | Treatment Sequence B+A | M1 | 4.00 | Full Range 3.00 to 4.03 | hour |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03316131/results